Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1286results about "Drug screening" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Generation of adipose tissue and adipocytes
The invention provides novel methods by which adipose tissue, preadipocytes, and adipocytes can be generated for research purposes, and methods for identifying cell populations that can proliferate and differentiate into adipocytes in vivo. The invention further provides a means for the in vivo derivation of “designer” or “customized” adipose tissue, preadipocytes, and adipocytes. Also provided are methods for identifying agents that affect adipocytes and adipose tissue, as well as the agents themselves. In particular, the present invention allows for creation of tissues and cells that can be used to screen for agents useful for treating human disorders associated with adipose tissue, including obesity, metabolic syndrome, and diabetes.
Owner:LOREM VASCULAR PTE LTD
Placental derived stem cells and uses thereof
The present invention features novel placental derived stem cells and provides methods and compositions for the therapeutic uses of placental derived stem cells or placental derived stem cells that have been induced to differentiate into a desired tissue type into a recipient host in amounts sufficient to result in production of the desired cell type, i.e., hepatic, pancreatic, neuronal, or nervous tissue.
Owner:UNIVERSITY OF PITTSBURGH
Cellular compositions and methods of making and using them
InactiveUS20050074435A1Increase the number ofEasy to collectPeptide/protein ingredientsDrug screeningProgenitorHematopoietic cell
The invention relates to cellular compositions comprising hematopoietic cells with the potential or increased potential to form non-hematopoietic cells; methods for producing such cellular compositions; methods for differeentitation of cells of cellular compositions of the invention into cells that exhibit morphological, physiological, functional, and / or immunological features of non-hematopoietic cells; and uses of the cellular compositions. The invention also relates to a method for the expansion of hemtopoietic stem and progenitor cells.
Owner:MOUNT SINAI HOSPITAL
Pluripotential embryonic stem cells and methods of making same
The present invention provides a non-mouse, including human, pluripotential embryonic stem cell which can:(a) be maintained on feeder layers for at least 20 passages; and(b) give rise to embryoid bodies and multiple differentiated cell phenotypes in monolayer culture.The invention further provides a method of making a pluripotential embryonic stem cell comprising culturing germ cells and germ cell progenitors in a composition comprising a growth enhancing amount of basic fibroblast growth factor, leukemia inhibitory factor, membrane associated steel factor, and soluble steel factor to primordial germ cells under cell growth conditions, thereby making a pluripotential embryonic stem cell.Also provided are compositions useful to produce the pluripotent embryonic stem cells and methods of screening associated with the method of making the embryonic stem cell.
Owner:VANDERBILT UNIV
Isolation and use of solid tumor stem cells
InactiveUS6984522B2Improved anti-cancer drug discoveryPromote resultsAnimal cellsMicrobiological testing/measurementAbnormal tissue growthCancer therapy
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
Owner:RGT UNIV OF MICHIGAN
Medium for growing human embryonic stem cells
InactiveUS7297539B2Rapid productionExpanding primate pluripotent stem (pPS) cellsHepatocytesGastrointestinal cellsGerm layerFiber
Owner:ASTERIAS BIOTHERAPEUTICS INC
Isolation And Use Of Solid Tumor Stem Cells
InactiveUS20080178305A1Reduce spreadIncreased proliferationMaterial nanotechnologyMicrobiological testing/measurementAbnormal tissue growthMammary gland structure
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumor cells in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
Owner:ONCOMED PHARMA +1
Pluripotent cell lines and methods of use thereof
InactiveUS20100167286A1Microbiological testing/measurementDrug screeningSequence variationBioinformatics
Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
Osteocyte cell lines
The present invention relates to a method of producing osteocyte cell line in various stages of differentiation. Such cell line remains stable after more than 20 passages. The osteocyte has a stellate shape with dendritic processes and expresses high level of osteocalcin. More specifically, it provides a method of production for cultured osteocytes of various differentiation stages. Furthermore, it relates to osteocyte cell line, and more specifically cultured osteocyte. The invention also relates to a method for the production of monoclonal antibodies using such cultured osteocytes and further relates to hybridomas and monoclonal antibodies which recognize an osteocyte-specific antigen. Finally, the invention relates to a method of screening for modification factors and binding factors for osteocytes.
Owner:BOARD OF REGENTS
Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
InactiveUS20100273160A1Reduce self-renewal capacityReduce spreadHepatocytesMicrobiological testing/measurementPhysiologyOvarian cancer
The present invention relates to compositions and methods for treating, characterizing and diagnosing ovarian cancer. In particular, the present invention provides methods for treating and / or preventing ovarian cancer in a subject by administering to the subject an effective amount of Mullerian Inhibiting substance and / or an effective amount of an agent that inhibits BCRP1. The present invention further provides methods to identify and / or enrich for populations of ovarian cancer stem cells and populations of somatic ovarian stem cells, in particular, enrichment for populations of coelomic somatic ovarian stem cells, subcoelomic / stromal somatic ovarian stem cells and periphilar medullary somatic ovarian stem cells. The present invention also provides somatic ovarian stem cell markers and ovarian cancer stem cell markers, as well as methods to identify agents which selectively inhibit the proliferation of ovarian cancer stem cells as compared to somatic ovarian stem cells.
Owner:THE GENERAL HOSPITAL CORP
Genetic products differentially expressed in tumors and the use thereof
ActiveUS7527933B2Improve cell activityEfficient disseminationCompound screeningApoptosis detectionCancer researchDisease cause
The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
Owner:GANYMED PHARMA AG
Compositions enriched in neoplastic stem cells and methods comprising same
A neoplastic stem cell population enriched for expression of the OCT4 transcription factor as well as methods for their identification, isolation and enrichment are described. The OCT4-enriched neoplastic stem cell population is further utilized for the induction and analysis of cancer in an animal. In addition, methods of preventing, abrogating, or inhibiting cancer, tumor growth, and metastasis via OCT4 inhibition are further provided.
Owner:UNIV OF TENNESSEE RES FOUND
Method of forming pancreatic beta cells from mesenchymal cells
InactiveUS20050208029A1Easy to separateBiocidePancreatic cellsScreening methodBULK ACTIVE INGREDIENT
It is intended to provide a method of forming pancreatic β cells from mesenchymal cells characterized by comprising using mammal-origin mesenchymal cells as starting cells, culturing these cells in the presence of, for example, a pancreatic β cell-forming agent, and selecting and separating the thus obtained pancreatic βcells with the use of a gene expressed specifically in such cells as a selection marker; a remedy for glucose intolerance which comprises pancreatic β cells obtained by the above method as the active ingredient; a pancreatic β cell-forming agent such as a cytokine to be used in the above method; a method of screening a candidate compound promoting the formation of pancreatic β cells from mesenchymal cells; and a pancreatic β cell formation promoter obtained by this screening method.
Owner:OTSUKA PHARM CO LTD
Genetically modified human natural killer cell lines
ActiveUS8313943B2Increase rangeHelp studyDrug screeningImmunoglobulins against cell receptors/antigens/surface-determinantsFc(alpha) receptorFc receptor
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
Owner:INST FOR CANCER RES
Method of generating human retinal progenitors from embryonic stem cells
Methods are provided for the in vitro differentiation of human retinal progenitor cells from embryonic stem cells.
Owner:UNIV OF WASHINGTON
Method for activating receptor by cofactor and method for utilizing ligand activity
InactiveUS20100184665A1Increase and inhibits activityExcellent screening systemCompound screeningOrganic active ingredientsCell systemBULK ACTIVE INGREDIENT
Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and / or betaKlotho on the surface thereof.
Owner:NAT INST OF ADVANCED IND SCI & TECH
Medium for growing human embryonic stem cells
InactiveUS20050037492A1Rapid productionCost-effectiveDrug screeningNervous system cellsGerm layerLipid formation
This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of mouse embryonic fibroblast feeder cells to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by defined components added to the culture environment that support rapid proliferation without differentiation. The medium contains an isotonic buffer, a blend of essential nutrients such as protein and lipids, and an effective growth factor or combination of factors that promote proliferation while inhibiting differentiation. Culturing human embryonic stem cells in fresh medium on an extracellular matrix according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.
Owner:ASTERIAS BIOTHERAPEUTICS INC
Protocols for making hepatocytes from embryonic stem cells
InactiveUS20050037493A1Promote cell differentiationCulture processDrug screeningGerm layerPluripotential stem cell
This disclosure provides a newly developed strategy and particular options for differentiating pluripotent stem cells into cells of the hepatocyte lineage. Many of the protocols are based on a strategy in which the cells are first differentiated into early germ layer cells, then into hepatocyte precursors, and then into mature cells. The cells obtained have morphological features and phenotypic markers characteristic of human adult hepatocytes. They also show evidence of cytochrome p450 enzyme activity, validating their utility for commercial applications such as drug screening, or use in the manufacture of medicaments and medical devices for clinical therapy.
Owner:ASTERIAS BIOTHERAPEUTICS INC
Expansion of renewable stem cell populations
ActiveUS20050008624A1Maximize expansionReduce capacityBiocideGenetic material ingredientsEx vivoImmunology
Owner:GAMIDA CELL
Process for making transplantable cardiomyocytes from human embryonic stem cells
InactiveUS20050054092A1Efficient productionGenetically modified cellsDrug screeningDiseaseHuman cell
This invention provides populations human cells of the cardiomyocyte lineage. The cells are obtained by causing cultures of pluripotent stem cells to differentiate in vitro, and then harvesting cells with certain phenotypic features. Differentiated cells bear cell surface and morphologic markers characteristic of cardiomyocytes, and a proportion of them undergo spontaneous periodic contraction. Highly enriched populations of cardiomyocytes and their replicating precursors can be obtained, suitable for use in a variety of applications, such as drug screening and therapy for cardiac disease.
Owner:ASTERIAS BIOTHERAPEUTICS INC
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
ActiveUS20160339019A1Cause deathReduce the possibilityPowder deliveryOrganic active ingredientsObstructive Pulmonary DiseasesAtheroma
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES +3
Differentiation of human embryonic stem cells
ActiveUS20110151561A1High expressionPancreatic cellsEpidermal cells/skin cellsPluripotential stem cellIntracrine
The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to increase the expression of NGN3 and NKX6.1 in populations of cells expressing markers characteristic of the pancreatic endocrine lineage.
Owner:JANSSEN BIOTECH INC
Expansion of renewable stem cell populations using modulators of PI 3-kinase
InactiveUS20050054103A1Raise the ratioMaximizing ex-vivo expansionHepatocytesMicroorganismsKinase activityBiochemistry
Owner:GAMIDA CELL
Culture media for stem cells
PendingUS20140243227A1Slow proliferationIncrease surface areaBioreactor/fermenter combinationsBiological substance pretreatmentsStem cell cultureBiology
Culture media and methods for expanding and differentiating populations of stem cells and for obtaining organoids. Expanded cell populations and organoids obtainable by methods of the invention and their use in drug screening, toxicity assays and regenerative medicine.
Owner:KONINK NEDERLANDSE AKADE VAN WETENSCHAPPEN
Extended primary retinal cell culture and stress models, and methods of use
A cell culture system related to extended in vitro culture of mature retinal cells and methods for preparing the cell culture system are provided. Also provided is a retinal cell culture stress model related to extended in vitro culture of mature retinal cells in the presence of a stressor and methods for using the cell culture stress model. The invention provides a cell culture system comprising a long-term culture of mature retinal cells, without requiring addition of other types of non-retinal cells such as purified glia, or cells isolated from ciliary bodies within the eye, and the addition of a stressor such as light, A2E, cigarette smoke condensate, glutamate, or hydrostatic pressure. Methods for identifying bioactive agents that alter viability, neurodegeneration, or survival of retinal cells using the retinal cell culture stress system are also provided.
Owner:ACUACELA INC
Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
InactiveUS20070166816A1Precise absorptionMaterial nanotechnologyBioreactor/fermenter combinationsAssayCell type
This invention provides device for co-culturing at least two different cell types in a two-dimensional configuration, methods of patterning at least two different cell types in a two-dimensional co-culture configuration, and uses of these devices and methods for analyzing an effect of candidate compound on such cellular cocultures. Also provided is a transmigration and extravasation device. Assay devices for analyzing the absorption, permeability, metabolism and / or toxicity of a candidate compound by a cell are provided. A microfluidic network, which is adaptable for integration with a device for coculturing is provided.
Owner:SURFACE LOGIX INC
Medium for growing human embryonic stem cells
InactiveUS7455983B2Cost-effectiveRapid productionMicroorganismsDrug screeningGerm layerLipid formation
Owner:ASTERIAS BIOTHERAPEUTICS INC
Methods And Means Related To Cancer Stem Cells
ActiveUS20080132423A1Promote more developedPromote growthMicrobiological testing/measurementLibrary screeningCancer cellPresent method
This invention relates to the methods for the identification and isolation of cancer stem cells from cultured cancer cell lines. Cell line-derived cancer stem cells isolated using the present methods may be useful, for example, in assays to screen compounds for anti-cancer stem cell activity and in target discovery methods for identifying novel expressed genes and druggable targets. The invention also relates to the screening of compounds for activity against cell line-derived cancer stem cells.
Owner:CAMBRIDGE ENTERPRISE LTD
Methods of generating human cardiac cells and tissues and uses thereof
A method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype is disclosed. The method comprises (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting said cell aggregates to culturing conditions suitable for generating embryoid bodies; (c) subjecting said embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of said embryoid bodies, said culturing conditions suitable for inducing cardiac lineage differentiation including adherence of said embryoid bodies to a surface, and culture, medium supplemented with serum, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype.
Owner:TECHNION RES & DEV FOUND LTD
Muir-Torre-like syndrome in Fhit deficient mice
InactiveUS20060075511A1Drug screeningNucleic acid vectorParanasal Sinus CarcinomaGastrointestinal cancer
The invention provides nonhuman transgenic animals with a disrupted FHIT gene. The invention further provides transgenic mice in which one or both Fhit alleles have been inactivated. Preferably, the Fhit-deficient mice develop multiple tumors of both visceral and sebaceous origin, similar to those of Muir-Torre familial cancer syndrome. The present invention further relates to the generation of these transgenic mice and their use as model systems to study the effects of carcinogenic agents in promoting clonal expansion of neoplastic cells in cancers, preferably gastrointestinal cancers of which Muir-Torre syndrome is a subset. The invention further relates to testing therapeutic agents for their efficacy in the prevention and treatment of cancer, preferably gastrointestinal cancer.
Owner:CROCE CARLO +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com